TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation

Oncogene

Volumn 27, Issue 40, 2008, Pages 5348-5353

  Sun, C ^a   Dobi, A ^a,f   Mohamed, A ^a   Li, H ^a   Thangapazham, R L ^a   Furusato, B ^a,b   Shaheduzzaman, S ^a   Tan, S H ^a   Vaidyanathan, G ^a   Whitman, E ^a,c   Hawksworth, D J ^a,c   Chen, Y ^a   Nau, M ^d   Patel, V ^e   Vahey, M ^d   Gutkind, J S ^e   Sreenath, T ^a   Petrovics, G ^a   Sesterhenn, I A ^b,f   McLeod, D G ^a,c,f   Srivastava, S ^a,f   more..

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^e NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^f United States Military Cancer Institute   (United States)

Author keywords

C MYC; ERG; Oncogene; Prostate cancer; PSA; TMPRSS2 ERG

Indexed keywords

SMALL INTERFERING RNA; TRANSCRIPTOME;

ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL GROWTH; GENE ACTIVATION; GENE FUSION; GENE MUTATION; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOLECULAR GENETICS; ONCOGENE C MYC; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATE EPITHELIUM; SEVERE COMBINED IMMUNODEFICIENCY; TMPRSS2 ERG GENE;

ANIMALS; BLOTTING, WESTERN; CELL DIFFERENTIATION; GENE EXPRESSION PROFILING; HUMANS; MALE; MEMBRANE PROTEINS; MICE; MICE, SCID; ONCOGENE PROTEINS, FUSION; PROMOTER REGIONS (GENETICS); PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

ANIMALIA; MUS;

EID: 51649115957     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.183     Document Type: Article

References (22)

1. Baldus CD, Burmeister T, Martus P, Schwartz S, Gokbuget N, Bloomfield CD et al. (2006). High expression of the ETS transcription factor ERG predicts adverse outcome in acute T-lymphoblastic leukemia in adults. J Clin Oncol 24: 4714-4720.
2. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG et al. (2007). Inflammation in prostate carcinogenesis. Nat Rev Cancer 7: 256-269.
3. Demichelis F, Rubin MA. (2007). TMPRSS2-ETS fusion prostate cancer: biological and clinical implications. J Clin Pathol 60: 1185-1186.
4. Furusato B, Gao CL, Ravindranath L, Chen Y, Cullen J, McLeod DG et al. (2008). Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Mod Pathol 21: 67-75.
5. Iljin K, Wolf M, Edgren H, Gupta S, Kilpinen S, Skotheim RI et al. (2006). TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res 66: 10242-10246.
6. Klezovitch O, Risk M, Coleman I, Lucas JM, Null M, True LD et al. (2008). A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci USA 105: 2105-2110.
7. Korenchuk S, Lehr JE, Mclean L, Lee YG, Whitney S, Vessella R et al. (2001). VCaP, a cell-based model system of human prostate cancer. In Vivo 15: 163-168.
8. Lin B, Ferguson C, White JT, Wang S, Vessella R, True LD et al. (1999). Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res 59: 4180-4184.
9. Marcucci G, Mrozek K, Bloomfield CD. (2005). Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics. Curr Opin Hematol 12: 68-75.
10. Massie CE, Adryan B, Barbosa-Morais NL, Lynch AG, Tran MG, Neal DE et al. (2007). New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Rep 8: 871-878.
11. Meulia T, Krumm A, Spencer C, Groudine M. (1992). Sequences in the human c-myc P2 promoter affect the elongation and premature termination of transcripts initiated from the upstream P1 promoter. Mol Cell Biol 12: 4590-4600.
12. Oettgen P, Finger E, Sun Z, Akbarali Y, Thamrongsak U, Boltax J et al. (2000). PDEF, a novel prostate epithelium-specific ets transcription factor, interacts with the androgen receptor and activates prostate-specific antigen gene expression. J Biol Chem 275: 1216-1225.
13. Owczarek CM, Portbury KJ, Hardy MP, O'Leary DA, Kudoh J, Shibuya K et al. (2004). Detailed mapping of the ERG-ETS2 interval of human chromosome 21 and comparison with the region of conserved synteny on mouse chromosome 16. Gene 324: 65-77.
14. Petrovics G, Liu A, Shaheduzzaman S, Furasato B, Sun C, Chen Y et al. (2005). Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 24: 3847-3852.
15. Scherf M, Epple A, Werner T. (2005). The next generation of literature analysis: integration of genomic analysis into text mining. Brief Bioinform 6: 287-297.
16. Seth A, Watson DK. (2005). ETS transcription factors and their emerging roles in human cancer. Eur J Cancer 41: 2462-2478.
17. Shaheduzzaman S, Vishwanath A, Furusato B, Cullen J, Chen Y, Banez L et al. (2007). Silencing of lactotransferrin expression by methylation in prostate cancer progression. Cancer Biol Ther 6: 1-8.
18. Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS et al. (2007). Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448: 595-599.
19. Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE et al. (2008). Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10: 177-188.
20. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW et al. (2005). Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644-648.
21. Turner DP, Watson DK. (2008). ETS transcription factors: oncogenes and tumor suppressor genes as therapeutic targets for prostate cancer. Expert Rev Anticancer Ther 8: 33-42.
22. Witte JS. (2007). Multiple prostate cancer risk variants on 8q24. Nat Genet 39: 579-580.